Sole Bookrunner, Broker and Nominated Adviser to Arecor Therapeutics

    News Read

Panmure Gordon is delighted to have acted as sole Bookrunner, Broker and Nominated Adviser to Arecor Therapeutics on their recent placing to raise £6.0 million and acquisition of Tetris Pharma, a commercial stage speciality pharmaceutical company.

The proceeds of the Placing will be used to support the acquisition of Tetris Pharma which will add a key commercial diabetes product to Arecor’s portfolio and will help realise Arecor’s vision of becoming a significant self-sustaining biopharmaceutical business.”

Panmure Gordon team includes:

Freddy Crossley, Emma Earl and Mark Rogers – Investment Banking Division

Rupert Dearden – Corporate Broking

David Cox – Specialist Sales

Julie Simmonds – Research

Emma Earl

Managing Director, Healthcare, Investment Banking

Freddy Crossley

Managing Director, Head of Healthcare

Rupert Dearden

Managing Director, Corporate Broking

David Cox

Director, Healthcare Specialist

Other insights like this

View all